CAMP4 Therapeutics Corp
CAMP6.000USD
-0.380-5.96%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
281.28MMarket Cap
LossP/E TTM
More Details of CAMP4 Therapeutics Corp Company
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
CAMP4 Therapeutics Corp Info
Ticker SymbolCAMP
Company nameCAMP4 Therapeutics Corp
IPO dateOct 11, 2024
CEOMandel-Brehm (Josh)
Number of employees55
Security typeOrdinary Share
Fiscal year-endOct 11
AddressOne Kendall Square
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16176518867
Websitehttps://www.camp4tx.com/
Ticker SymbolCAMP
IPO dateOct 11, 2024
CEOMandel-Brehm (Josh)
Company Executives of CAMP4 Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.42K
+2.23%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
170.01K
+9.78%
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Ms. Kelly Gold
Ms. Kelly Gold
Chief Financial Officer
Chief Financial Officer
67.88K
+9.80%
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
28.74K
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.50K
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Independent Director
Independent Director
--
--
Dr. Yuri Maricich, M.D.
Dr. Yuri Maricich, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Amir H. Nashat
Dr. Amir H. Nashat
Independent Director
Independent Director
--
--
Mr. Andrew J. (Andy) Schwab
Mr. Andrew J. (Andy) Schwab
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.42K
+2.23%
Dr. Richard A. (Rick) Young, Ph.D.
Dr. Richard A. (Rick) Young, Ph.D.
Independent Director
Independent Director
170.01K
+9.78%
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Independent Director
Independent Director
108.95K
--
Ms. Kelly Gold
Ms. Kelly Gold
Chief Financial Officer
Chief Financial Officer
67.88K
+9.80%
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
28.74K
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.50K
--
Revenue Breakdown
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.50M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
5AM Ventures
11.31%
Coastlands Capital LP
9.42%
Janus Henderson Investors
8.95%
Polaris Partners
7.58%
Vivo Capital, LLC
7.56%
Other
55.18%
Shareholders
Shareholders
Proportion
5AM Ventures
11.31%
Coastlands Capital LP
9.42%
Janus Henderson Investors
8.95%
Polaris Partners
7.58%
Vivo Capital, LLC
7.56%
Other
55.18%
Shareholder Types
Shareholders
Proportion
Venture Capital
27.28%
Hedge Fund
15.23%
Corporation
14.88%
Investment Advisor/Hedge Fund
9.74%
Investment Advisor
6.56%
Private Equity
2.45%
Individual Investor
1.35%
Other
22.52%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
77
26.90M
24.28%
--
2025Q3
77
26.90M
56.46%
+16.46M
2025Q2
70
10.43M
46.48%
-969.10K
2025Q1
63
11.40M
45.72%
+2.19M
2024Q4
50
11.49M
32.44%
+4.95M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
5AM Ventures
8.81M
43.7%
+5.88M
+200.91%
Sep 11, 2025
Polaris Partners
3.93M
19.5%
+1.31M
+49.80%
Sep 11, 2025
Vivo Capital, LLC
3.92M
19.45%
+3.92M
--
Sep 11, 2025
Enavate Sciences GP, LLC
3.79M
18.78%
--
--
Sep 11, 2025
Fidelity Management & Research Company LLC
3.02M
15%
+2.42M
+397.32%
Sep 30, 2025
Northpond Ventures, LLC
2.24M
11.1%
+2.24M
--
Oct 22, 2024
Andreessen Horowitz
2.13M
10.54%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CAMP4 Therapeutics Corp?
The top five shareholders of CAMP4 Therapeutics Corp are:
5AM Ventures holds 8.81M shares, accounting for 43.70% of the total shares.
Polaris Partners holds 3.93M shares, accounting for 19.50% of the total shares.
Vivo Capital, LLC holds 3.92M shares, accounting for 19.45% of the total shares.
Enavate Sciences GP, LLC holds 3.79M shares, accounting for 18.78% of the total shares.
Fidelity Management & Research Company LLC holds 3.02M shares, accounting for 15.00% of the total shares.
5AM Ventures holds 8.81M shares, accounting for 43.70% of the total shares.
Polaris Partners holds 3.93M shares, accounting for 19.50% of the total shares.
Vivo Capital, LLC holds 3.92M shares, accounting for 19.45% of the total shares.
Enavate Sciences GP, LLC holds 3.79M shares, accounting for 18.78% of the total shares.
Fidelity Management & Research Company LLC holds 3.02M shares, accounting for 15.00% of the total shares.
What are the top three shareholder types of CAMP4 Therapeutics Corp?
The top three shareholder types of CAMP4 Therapeutics Corp are:
5AM Ventures
Coastlands Capital LP
Janus Henderson Investors
5AM Ventures
Coastlands Capital LP
Janus Henderson Investors
How many institutions hold shares of CAMP4 Therapeutics Corp (CAMP)?
As of 2025Q4, 77 institutions hold shares of CAMP4 Therapeutics Corp, with a combined market value of approximately 26.90M, accounting for 24.28% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -32.18%.
What is the biggest source of revenue for CAMP4 Therapeutics Corp?
In FY2025Q2, the -- business generated the highest revenue for CAMP4 Therapeutics Corp, amounting to -- and accounting for --% of total revenue.
